GenCurix announced on the 28th that it will begin collaboration with Japan's Hitachi High-Tech Corporation on cancer molecular diagnostics business.
Through this collaboration, GenCurix's expertise in selecting key biomarkers in the cancer field, molecular diagnostic product development, and service experience will be combined with Hitachi High-Tech's long-standing research and development, manufacturing experience, and digital technology in the in vitro diagnostics field. They will start full-scale cooperation for commercialization in Japan.
Recently, when treating cancer, genes or proteins are examined in detail to select therapeutic drugs. Personalized medicine tailored to individual patients is expanding. In the cancer treatment field, where new therapeutic drugs and methods are developed, there is a demand for discovering appropriate biomarkers, establishing testing methods, and providing rapid and medically valuable results using digital technology.
GenCurix is a cancer molecular diagnostics specialist company that provides Digital-PCR based products and testing services, based on liquid biopsy and biomarker discovery and commercialization platforms. Major products include GenesWell BCT, a prognostic test for breast cancer, and the Droplex product line capable of companion diagnostics for various cancer types such as lung cancer, colorectal cancer, and endometrial cancer. They are developing early diagnostic tests for major cancers such as liver cancer and colorectal cancer and conducting clinical research.
In Japan, Hitachi High-Tech's healthcare business will succeed Hitachi, Ltd.'s healthcare business in April 2024, aiming to create healthcare innovation through 'diagnostics x treatment x digital.' In the in vitro diagnostics field, they have a product lineup including biochemical and immunoassay analyzers that analyze specimens such as blood to support disease diagnosis, as well as DNA sequencers, contributing to high quality and efficiency in clinical testing.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
